A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Saved in:
| Title: | A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy. |
|---|---|
| Authors: | Cosden, Mali1 (AUTHOR), Jinn, Sarah1 (AUTHOR), Yao, Lihang1 (AUTHOR), Gretzula, Cheryl A.1 (AUTHOR), Kandebo, Monika1 (AUTHOR), Toolan, Dawn1 (AUTHOR), Hatcher, Nathan G.1 (AUTHOR), Ma, Lei1 (AUTHOR), Lemaire, Wei2 (AUTHOR), Adam, Gregory C.2 (AUTHOR), Burlein, Christine2 (AUTHOR), Minnick, Christina2 (AUTHOR), Flick, Rose2 (AUTHOR), Watt, Marla L.2 (AUTHOR), Mulhearn, James3 (AUTHOR), Fraley, Mark3 (AUTHOR), Drolet, Robert E.1 (AUTHOR), Marcus, Jacob N.1 (AUTHOR), Smith, Sean M.1 (AUTHOR) sean_smith2@merck.com |
| Source: | Neurobiology of Disease. Nov2021, Vol. 159, pN.PAG-N.PAG. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
